⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVL News
Nuvalent, Inc. Class A Common Stock
Nuvalent to Present New Preclinical Data for HER2-Selective Inhibitor, NVL-330, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
prnewswire.com
NUVL
NUVL
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
prnewswire.com
NUVL
NUVL
Nuvalent Presents Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025
prnewswire.com
NUVL
NUVL